EpiCeram
ApprovedSmall molecule
EpiCeram is one of 36 small molecule programs targeting Food Allergy. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Skyrizi
AbbViePhase 3
Fludara
SanofiPhase 3
Nereus
VVanda Pharmaceuticals
Phase 3
Celestone
SSchering-Plough
Phase 3
Flovent
PParatek Pharmaceuticals Inc
Phase 3
EpiCeram
SStanford University
Approved
Adquey
AAcrotech Biopharma Inc.
Phase 3
Fucidin
LEO PharmaPhase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EpiCeram. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SStanford University